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develop distant metastases. Additionally, cancer 
cells in the bone marrow may be dormant for 
several years before re ‑entering the circulation; 
however, such situations are very uncommon in 
colorectal cancer. Two meta ‑analyses of studies on 
the prognostic significance of circulating cancer 
cells in colorectal cancer indicated that the pres‑
ence of DTCs in the peripheral blood is a nega‑
tive prognostic factor.2,3
At present, there is insufficient evidence to 
confirm that the presence of DTCs in the bone 
marrow of patients with colorectal cancer affects 
IntroductIon The significance of disseminat‑
ed tumor cells (DTCs) in the bone marrow of pa‑
tients with colorectal cancer is unclear. The pres‑
ence of DTCs in the bone marrow is identified in 
17% to 64% of this population (median, 29%).1 
These cells are a subset of circulating tumor cells 
that migrate to the bone marrow and can form 
micrometastases. This phenomenon is mostly de‑
scribed in patients with breast cancer. Although 
DTCs in the bone marrow are present in a sub‑
stantial percentage of cancer patients without dis‑
tant or nodal metastases, most of them will not 
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AbstrAct
IntroductIon Disseminated tumor cells (DTCs) are a subset of circulating tumor cells that migrate to 
the bone marrow. Colorectal cancer is a heterogeneous disease depending on the site of the primary tumor.
objEctIvEs We aimed to assess the association between the presence of DTCs in the bone marrow and 
tumor characteristics as well as long ‑term treatment outcomes in patients with left ‑sided colorectal cancer.
PAtIEnts And mEthods This prospective study included 91 patients with left ‑sided colorectal cancer 
(37 with colon cancer and 54 with rectal cancer) treated between 2007 and 2012 in a single tertiary 
center. Fifteen patients had stage I cancer; 26, stage II; 26, stage III; and 24, stage IV. Overall survival 
and cancer relapse rates were compared between patients with different cancer stages and DTC status.
rEsuLts Bone marrow DTCs were identified in 42 patients (46.1%). The prevalence of DTCs was not 
related to tumor infiltration depth, nodal involvement, distant metastasis, tumor stage, or primary tumor 
site. The 5 ‑year overall survival rates were 59.5% and 53% in the DTC ‑positive and DTC ‑negative groups, 
respectively (P = 0.19). There was a notable trend favoring survival in patients with DTCs with stage 
II and III disease (both separately and when combined). The number of metachronous distant metastases 
was significantly lower in DTC‑positive patients.
concLusIons The presence of DTCs in the bone marrow is not associated with primary tumor charac‑
teristics and seems to reduce metastasis formation in left ‑sided colorectal cancer. There is also a trend 
for improved overall survival in DTC‑positive patients. These results are intriguing and warrant further 
confirmation.
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washed in phosphate‑buffered saline (PBS) and 
adjusted to the concentration of 1 × 107 cells ml−1 in 
PBS. Subsequently, the cells were stained with 
monoclonal mouse antihuman CD45 (phycoery‑
thrin‑labeled) antibodies (DAKO, Glostrup, Den‑
mark) and sorted into CD45+ and CD45− popu‑
lations using flow cytometry (FACS Vantage SE, 
BD Biosciences, Bedford, Massachusetts, Unit‑
ed States) equipped with the TurboSort option 
(BD Biosciences) and Aerosol Protection Sys‑
tem (Flexoduct International ApS, Greve, Den‑
mark). The Innova Enterprise II ion laser (Co‑
herent, Santa Clara, California, United States) 
operating at 488 nm was used as a light source. 
Sorting was performed using a 70 ‑mm nozzle tip 
with a drop drive frequency of 65 kHz, 1.5 ‑drop 
envelopes and a “normal” sorting mode. Sorted 
CD45− cells were collected into polystyrene Fal‑
con 2057 tubes (BD Biosciences) precoated with 
fetal calf serum and maintained in a refrigerat‑
ed bath recirculator (Neslab Instruments, Ports‑
mouth, New Hampshire, United States). About 
1 × 106 of CD45– cells (1 × 106 cells ml−1) were used 
to prepare slides. The slides were dried, fixed with 
a mixture of ethanol and acetone (1: 1 v v−1), and 
then stained for 30 minutes with A45 ‑B/B3 mo‑
noclonal antibodies (5 µg ml−1) (Micromet GmbH, 
Munich, Germany), which recognize common epi‑
topes of cytokeratins (CKs) including CK8, CK18, 
and CK19. Subsequently, the slides were washed 
and stained for 30 minutes with goat anti ‑mouse 
IgG ‑FITC ‑labeled antibodies (DAKO). After wash‑
ing with PBS, the slides were assayed within 2 
days. The CK+ cells were identified by 2 indepen‑
dent investigators under a BX60 fluorescent mi‑
croscope (Olympus, Tokyo, Japan) and document‑
ed with a DP10 camera (Olympus). At least 300 
cells were examined per slide. The samples were 
regarded as positive when at least 3 CK+ cells were 
found per slide. Accordingly, patients were clas‑
sified into CK+ and CK− groups. All CK+ cells were 
cytologically malignant cells as seen under the mi‑
croscope. We could not distinguish between differ‑
ent CKs. However, the antibody (A45 ‑B/B3) was 
commonly used in research on DTCs in the bone 
marrow, so the comparison with other studies is 
possible. The cytokeratins CK8, CK18, and CK19 
are the epitopes of normal colonic mucosa, co‑
lonic adenoma, and adenocarcinoma. Therefore, 
the staining of the tumor for these epitopes is 
not routinely used and was not performed in our 
patients.
The surgical procedures were carried out ac‑
cording to oncology guidelines. Due to the chang‑
es in the TNM staging system during the study 
period, all the specimens were re ‑staged according 
to the seventh edition. The clinical and patholog‑
ical data were recorded. Patients received postop‑
erative chemotherapy if indicated, regardless of 
their DTC status. All patients were followed for 
at least 5 years or until death, and the dates of 
death were verified with the census registry office.
All patients provided written informed con‑
sent to participate in the study. The study was 
the prognosis.4-7 Such studies, especially those on 
non disseminated colorectal cancer, require a large 
number of patients and a long follow ‑up, because 
the median survival in patients with colorectal 
cancer undergoing radical surgery is longer than 
5 years. In addition, colorectal cancer is a heter‑
ogenous disease depending on the site affected 
by the primary tumor. What follows, right‑ and 
left ‑sided cancers may differ in terms of biolog‑
ical characteristics and prognosis.8-11 Therefore, 
in this study, we focused on malignancies arising 
from the left colon and rectum, with an emphasis 
on locally advanced cancer. In particular, we aimed 
to assess the relationship between the presence 
of DTCs in the bone marrow and tumor charac‑
teristics, cancer progression, and survival in pa‑
tients with left ‑sided colorectal cancer.
PAtIEnts And mEthods The study included 91 
patients with colorectal cancer treated at a sin‑
gle institution between 2007 and 2012. Only pa‑
tients with tumors located in the rectum or left 
colon were included. The term “left colon” was 
defined as a section of the colon distal to the left 
one ‑third of the transverse colon. The inclusion 
criteria were age over 18, histologically confirmed 
cancer, and elective surgical procedure. Patients 
with synchronous right ‑sided colon cancer or 
those with a history of other neoplastic diseases 
were excluded. None of the patients with colon 
cancer received preoperative chemotherapy, while 
5 patients with rectal cancer received preopera‑
tive radiotherapy and 2—preoperative chemora‑
diotherapy. The group included 42 women and 49 
men (mean [SD] age, 64.7 [10.2] years). The dis‑
tribution of cancer stage according to the TNM 
classification was as follows: T1, 2 patients; T2, 16; 
T3, 60; T4, 13; N0, 42; N1, 20; N2, 25; Nx, 4; M0, 
67; and M1, 24. The clinical and pathological char‑
acteristics of patients are summarized in tAbLE 1.
A bone marrow biopsy of the posterior supe‑
rior iliac spine was performed on the day of sur‑
gery after the induction of general anesthesia. 
A 5 ‑ml sample of the bone marrow was collected 
into plastic EDTA tubes.
Pelleted cells from bone marrow samples were 
incubated with an excessive amount of lysing so‑
lution (BD Biosciences, San Jose, California, Unit‑
ed States) for 10 minutes, repeated 3 to 4 times 
to remove erythrocytes. The remaining cells were 
whAt’s nEw?
Our study showed a significantly lower number of metachronous distant metas‑
tases in patients with left ‑sided colorectal carcinoma and disseminated tumor 
cells (DTCs) in the bone marrow than in those without DTCs. The presence 
of DTCs in the bone marrow was not a negative predictive factor of distant 
metastases or a negative prognostic factor in our study group. This supports 
the concept that there are substantial differences between the characteristics 
of colorectal cancer depending on affected sites. This issue should be ad‑
dressed in future studies in order to develop a tailored approach for patients 
with this malignancy.
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and was similar in patients with T1 ‑2 and T4 can‑
cer. There was no significant difference between 
the prevalence of DTCs in patients with and with‑
out distant metastasis. These patients also showed 
similar rates of DTC detection in the bone mar‑
row. The prevalence of DTCs in the bone marrow 
of patients with TNM stages I–IV was similar, 
with a slightly lower prevalence in patients with 
stage IV cancer. The presence of DTCs in the bone 
marrow was not related to either the tumor grade 
or radicality of resection.
The number of patients who received preoper‑
ative treatment was low. Nonetheless, 5 patients 
with rectal cancer received preoperative radiother‑
apy, and 3 of them had DTCs in the bone marrow. 
Moreover, 2 patients with rectal cancer received 
preoperative chemoradiotherapy, and 5 weeks 
after treatment completion, both of them were 
found to harbor DTCs in their bone marrow.
All patients were followed for at least 5 years. 
The 5 ‑year survival rate for DTC ‑positive patients 
was 59.5%, while for DTC ‑negative ones, it was 
53%. The difference between groups was not sig‑
nificant (FIGurE 1). As DTC could theoretically lead 
to distant metastasis and cancer progression, 
a further analysis of patients with stage II and 
III disease was performed. Stage IV patients were 
excluded, because they already had disseminat‑
ed disease, while stage I patients were excluded 
due to a very low probability of tumor progres‑
sion. In the group of patients with stages II and 
III, the 5 ‑year survival rates were 59.2% and 76% 
for DTC ‑negative and DTC ‑positive patients, re‑
spectively (FIGurE 2A). Even though the difference 
was almost 17% in favor of DTC ‑positive patients, 
it was not significant. The number of patients in 
stages II and III in the DTC ‑negative group was 
14 and 13, respectively, and in the DTC‑positive 
group, 12 and 13, respectively. The mean age of 
DTC ‑negative patients was 63 years, while in 
the DTC ‑positive group, it was 65.3 years. A trend 
towards better survival in DTC ‑positive patients 
was also observed when we analyzed patients 
with stages II and III cancer separately; howev‑
er, the number of patients was too small to ob‑
tain significant results (FIGurE 2b and 2c).
Disease recurrence was assessed in stages II 
and III. Metastatic disease was diagnosed in 13 
patients (25%). The sites of metastasis differed, 
with the prevalence of liver metastasis (7 of the 13 
patients). In the DTC ‑negative group, 10 cases 
of metastasis were observed, while in the DTC‑
‑positive group, only 3 cases (P = 0.038).
dIscussIon This study was started in 2007 and 
we decided to use methodology already estab‑
lished for gastric cancer in patients with colorec‑
tal cancer.12 The preliminary results were not 
published earlier, as such a study requires long‑
‑term follow ‑up. As of now, all participants have 
been followed for at least 5 years. Our popula‑
tion was more homogenous than those in oth‑
er studies, because we recruited only patients 
with left ‑sided colon and rectal cancer. Most 
approved by the Jagiellonian University Ethi‑
cal Committee (KBET no. 86/B/2007 and KBET 
no. 122.6120.128.2015) and was registered at Clini‑
calTrials.gov (registration number, NCT03640572).
statistical analysis The statistical analysis was 
conducted using the Statistica 13 software (Dell, 
Inc., Tulsa, Oklahoma, United States). The dis‑
tribution of variables was checked using the Kol‑
mogorov–Smirnov test. Categorical variables 
were compared with the χ2 test with Yates cor‑
rection. Survival analysis was performed accord‑
ing to the Kaplan–Meier method and log ‑rank 
test. A P value of less than 0.05 was considered 
significant.
rEsuLts In our study, CK+ cells were identified 
in the bone marrow of 42 patients (46.1%): 16 
patients with left ‑colon cancer (43.2%) and 26 
with rectal cancer (48.1%), without a significant 
difference (tAbLE 2). The prevalence of DTCs was 
not related to the depth of infiltration (T feature) 
tAbLE 1 Clinical and pathological characteristics of study patients
Parameter Patients, n (%)
Tumor location
Left colon 37 (41)
Rectum 54 (59)
Primary tumor
T1 2 (2)
T2 16 (18)
T3 60 (66)
T4 13 (14)
Lymph nodes
N0 42 (46)
N1 20 (22)
N2 25 (27.5)
Nx 4 (4.5)
Metastases
M0 67 (73.6)
M1 24 (26.4)
UICC / AJCC stage
I 15 (16.4)
II 26 (28.6)
III 26 (28.6)
IV 24 (26.4)
Grade
1 26 (28.55)
2 45 (49.45)
3 13 (14.3)
Not assessed 7 (7.7)
Resection margins
R0 63 (69.2)
R1 5 (5.5)
R2 23 (25.3)
Abbreviations: AJCC, American Joint Committee on Cancer; UICC, Union for 
International Cancer Control
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FIGurE 1 Cumulative 
survival in disseminated 
tumor cell (DTC)–positive 
and DTC ‑negative groups: 
all tumor stages
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tAbLE 2 Patients with cytokeratin ‑positive cells identified in the bone marrow
Parameter Left colon (16/37) Rectum (26/54) Both sites (42/91)
Tumor
T1–T2 0/3 10/15 (66.6) 10/18 (55)
T3 13/29 (44.8) 12/31 (38.7) 25/60 (41.7)
T4 3/5 (60) 4/8 (50) 7/13 (53.8)
Lymph nodes
N– 5/15 (33.3) 14/27 (51.9) 19/42 (45.2)
N+ 10/21 (47.6) 9/24 (37.5) 19/45 (42.2)
Nx 1/1 (100) 3/3 (100) 4/4 (100)
Metastases
M0 11/28 (39.2) 21/39 (53.8) 32/67 (47.7)
M1 5/9 (55.5) 5/15 (33.3) 10/24 (41.6)
Grade
G1–G2 12/29 (41.3) 21/42 (50) 33/71 (46.5)
G3 3/6 (50) 0/7 3/13 (23)
Not assessed 1/2 (50) 5/5 (100) 6/7 (85.7)
UICC / AJCC stage
I 0/3 7/12 (58.3) 7/15 (46.6)
II 5/12 (41.7) 7/14 (50) 12/26 (46.2)
III 6/13 (46.2) 7/13 (53.8) 13/26 (50)
IV 5/9 (55.5) 5/15 (33.3) 10/24 (41.6)
Resection margins
R0 10/28 (35.7) 20/35 (57.1) 30/63 (47.6)
R1 1/1 (100) 0/4 1/5 (20)
R2 5/8 (62.5) 6/15 (40) 11/23 (47.8)
Data are presented as the number of disseminated tumor cell–positive patients / the total number of patients with 
cancer of particular stage, grade, or resection margins (percentage).
Abbreviations: see tAbLE 1
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FIGurE 2 Cumulative 
survival in patients with 
stage II and III cancer (A) 
and stage II cancer (b) in 
disseminated tumor cell 
(DTC)–positive and DTC‑
‑negative groups
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investigations provided contradictory results.18,19 
There is also a common opinion that the tumor 
grade does not influence the rate of DTCs in the 
bone marrow.4,16
We observed no difference in the prevalence 
of DTCs between patients with left colon and 
those with rectal cancer. This is in line with oth‑
er studies.4,20 For patients with colon cancer, 
neoadjuvant therapy is the exception and not 
the standard treatment, but patients with rec‑
tal cancer may receive preoperative radiotherapy 
or chemoradiotherapy according to indications. 
In our study, only 7 patients with rectal cancer 
underwent preoperative treatment. While this 
number is low, this method was not used rou‑
tinely in the initial study period. It was not ex‑
pected that the short ‑course radiotherapy would 
affect DTCs; however, 5 weeks of chemoradio‑
therapy could potentially eradicate such cells. 
The study on DTCs in rectal cancer showed that 
they are identified less frequently in patients 
who responded to preoperative chemoradio‑
therapy.21 Moreover, in a study on gastric can‑
cer, chemotherapy was reported to significant‑
ly reduce the prevalence of DTCs in the bone 
marrow.22 We observed only 2 patients who re‑
ceived preoperative chemoradiotherapy. After 
this therapy, both of them were DTC positive. 
Although this observation has no statistical pow‑
er, it shows that the preoperative treatment did 
not bias the results in patients with rectal cancer.
The overall survival at 5 years was similar 
between the DTC ‑positive and DTC ‑negative 
groups. Both groups also had comparable can‑
cer stages according to the TNM classification. 
This finding alone is not surprising, as previous 
studies included patients with both left‑ and 
right ‑sided colorectal cancer or only those with 
rectal cancer. Right ‑sided colon cancer has dif‑
ferent clinical and molecular characteristics than 
left ‑sided colon and rectal cancer; therefore, it 
should be analyzed separately in clinical and sci‑
entific studies.13
In our study, DTCs in the bone marrow were 
diagnosed in 46.1% of patients. Other studies re‑
ported an incidence between 10% and 63.6% of 
cases,7,14 although the majority of studies report‑
ed a range between 25% and 40%. With the high 
number of epitopes of the tumor cells used and 
different methods of detection (immunocyto‑
chemistry, immunomagnetic assay, or reverse‑
‑transcription polymerase chain reaction), there 
is no standard method for identifying DTCs in 
the bone marrow.15 The rate of detection differs 
depending on the technique used, even with‑
in a single study.16,17 The method that we used 
in this study is based on fluorescence ‑activated 
cell sorting and the detection of cells expressing 
the common epitope of CK8, CK18, and CK19 
within the sorted population. Therefore, this ap‑
proach may be more sensitive than other simpler 
methods, because the cell population is enriched 
with the initial sorting.
In our study, the incidence of DTCs in the bone 
marrow was not related to the depth of tumor in‑
filtration, nodal involvement, or distant metasta‑
sis. A similar finding was described in a German 
study of patients with colon cancer.16 However, 
in that study, over 40% of patients had tumors in 
the right ‑sided colon. Our results were corrobo‑
rated also by other studies in diverse groups of pa‑
tients with colorectal cancer,4,7 while some other 
FIGurE 2 Cumulative 
survival in patients with 
stage III cancer (c) in 
disseminated tumor cell 
(DTC)–positive and DTC‑
‑negative groups
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do not influence cancer progression,29 but they do 
not focus on the beneficial effect of this phenome‑
non. Bone marrow is a specific site with a number 
of hematopoietic and immunocompetent cells and 
also stem cells. DTCs are present  during the gen‑
eration and maturation of various immunocom‑
petent cells. It was demonstrated that the gener‑
ation of monocytes from hematopoietic CD34+ 
stem cells from the bone marrow of patients with 
colon cancer is possible, and these cells act as 
antigen ‑presenting cells. They may present tumor‑
‑specific antigens to cytotoxic T lymphocytes.30 
Moreover, it was shown that after in vivo expo‑
sure to blood ‑derived cell ‑ and tumor ‑associated 
antigens, bone marrow dendritic cells were capa‑
ble of inducing systemic protective T cell–medi‑
ated antitumor immunity upon adoptive trans‑
fer.31 In contrast to the bone marrow, respons‑
es of lymph nodes to blood ‑circulating antigen 
were only weak. There is evidence that bone mar‑
row–derived dendritic cells differ from peripher‑
al blood–derived dendritic cells, but the signifi‑
cance of this difference is unclear.32
Bone marrow also seems to be a preferen‑
tial site for migration and / or selective retain‑
ment of memory T cells and becomes enriched 
with antigen ‑specific memory T lymphocytes 
in response to viral infection or tumor develop‑
ment.33,34 This mechanism may underlie the find‑
ing observed in our study. Surrounded by im‑
mune cells, DTCs may be the source of tumor‑
‑related antigens and generate an immune reac‑
tion against these antigens. Therefore, DTCs may 
act as a kind of cancer vaccination.
Previous studies have shown that blood circu‑
lating breast cancer cells may settle in the bone 
marrow and spleen. At  these sites, antigen‑
‑presenting cells may pick up, process, and cross‑
‑present tumor ‑associated antigens to prime na‑
ive T lymphocytes. This may lead to generation 
and maturation of specific effector and also mem‑
ory T cells. Particular clones of so activated cy‑
totoxic T lymphocytes, upon contact with tu‑
mor cells, may exhibit cytotoxic activity or even 
control dormant cancer foci.35 It was also pro‑
posed that small amounts of persisting tumor‑
‑associated antigens produced by dormant tu‑
mor cells from the bone marrow may contribute 
to the maintenance of tumor ‑specific and long‑
‑term memory mediated by appropriate subsets 
of memory T lymphocytes.36
The presence of DTCs in the bone marrow is 
not associated with primary tumor characteristics 
and seems to reduce metastasis formation in left‑
‑sided colorectal cancer. There is a trend for im‑
proved overall survival in DTC ‑positive patients.
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studies demonstrated that the presence of DTCs 
in the bone marrow may not be a negative prog‑
nostic factor in patients with colorectal cancer. 
This is also in line with conclusions from a meta‑
‑analysis published in 2010.23 However, the au‑
thors emphasized that the methods of DTC detec‑
tion were inhomogenous. Therefore, new studies 
with new populations of patients diagnosed us‑
ing a specific method are still needed. For further 
analysis in our study, we excluded patients with 
the most advanced disease stage, namely, stage 
IV. The prognostic significance of bone marrow 
DTCs was described in stage IV colorectal cancer, 
but only in patients after a curative resection of 
liver metastasis.24 On the other hand, other in‑
vestigators demonstrated that this phenomenon 
may be related to the method of detection.17 We 
were unable to identify a study that would show 
the prognostic significance of DTCs in patients 
with stage IV colorectal cancer who did not under‑
go a radical resection of metastasis. In our study, 
only 1 patient with stage IV cancer had a simulta‑
neous liver resection for metastasis. Also, stage I 
patients were excluded due to a very low proba‑
bility of cancer progression with definitive treat‑
ment. Other studies, especially those with small 
sample sizes, included stage I patients,5 but larg‑
er studies investigated mainly those with stage II 
and III disease.4 When patients with stages II and 
III were analyzed together, the 5 ‑year survival rate 
in our study was similar between patients with 
and without DTCs. These results are in contrast 
to a recent publication from Switzerland, where 
bone marrow cells were identified with the same 
type of pan ‑CK antibody, with a detection rate 
similar to that in our study, in patients with stag‑
es I–III. The authors found that the presence of 
DTCs in the bone marrow was a negative prog‑
nostic factor for survival.25 However, in contrast 
to our study, they excluded patients with rectal 
cancer and only about 40% of patients had left‑
‑sided cancer. Moreover, their findings were not 
corroborated by some other studies.7,20
In our study, the survival plots showed a trend 
favoring patients with DTCs in the bone marrow, 
but the results were not significant. Therefore, 
we attempted to assess the incidence of distant 
metastasis during the 5 ‑year follow ‑up. Theo‑
retically, tumor cells located in the bone marrow 
could be the source of distant metastasis. What 
follows is that there should be a correlation be‑
tween DTCs and metachronous metastasis. Such 
associations have been observed in breast,26 pros‑
tate,27 and esophageal cancer.28 Surprisingly, in 
our study, there was a significantly lower number 
of metachronous distant metastases in patients 
with DTCs than in those without. The reason for 
this finding may be the low number of patients; 
however, this number is not significantly lower 
than in the majority of similar studies of patients 
with the same TNM stages. This observation may 
indicate that the presence of DTCs might have 
prevented the progression and metastasis forma‑
tion. There are hypotheses explaining why DTCs 
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